Tumour-Infiltrating Clonal Haematopoiesis Increases the Risk of Recurrence or Death Among Patients with NSCLC and the Risk of Death From Any Cause Among Patients with Solid Tumours By Ogkologos - May 7, 2025 680 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the analysis of TRACERx and MSK-IMPACT studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Growing the Cancer Research Pipeline by Expanding Opportunities August 29, 2024 Cancer Rehabilitation Starts at Diagnosis: Part II July 13, 2021 Adding Pembrolizumab to Chemotherapy Results in Improved PFS and OS in... November 25, 2024 Nivolumab Plus Ipilimumab Demonstrates Long-Term Survival Benefit in Patients with Advanced... May 28, 2024 Load more HOT NEWS March is Colon Cancer Awareness Month ESMO Clinical Practice Guideline Express Update on the management of epithelial... Veteran Drops To The Ground When He Hears How Much His... Navigating Your Care During Long-Term Cancer Survivorship
